Recce Pharmaceuticals (ASX:RCE) said phase two clinical trials of its topical gel Recce 327 (R327G) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) showed that the gel is safe and well-tolerated with no serious adverse effects on patients, according to a Monday filing with the Australian bourse.
After 14 days of treatment, 27 out of 29 patients treated with R327G achieved the primary efficacy endpoint, the filing said.
The study's assessments observed wound healing, with the potential for full recovery after 14 days, the filing added.
Based on the trial's results, experts believe the company's registrational phase 3 study for diabetic foot infections can achieve a statistically "significant" positive endpoint after enrolling around 100 patients, the filing added.
Shares of the company rose past 2% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.